These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9077559

  • 1. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
    Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA.
    Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
    [Abstract] [Full Text] [Related]

  • 2. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA.
    Cancer Res; 1994 Feb 15; 54(4):1071-6. PubMed ID: 7508819
    [Abstract] [Full Text] [Related]

  • 3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.
    Cancer Res; 1998 Feb 15; 58(4):732-6. PubMed ID: 9485028
    [Abstract] [Full Text] [Related]

  • 4. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E.
    Cancer Res; 1999 Jan 15; 59(2):431-5. PubMed ID: 9927058
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.
    Cancer Res; 2006 May 15; 66(10):5452-60. PubMed ID: 16707474
    [Abstract] [Full Text] [Related]

  • 6. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
    Gritzapis AD, Fridman A, Perez SA, La Monica N, Papamichail M, Aurisicchio L, Baxevanis CN.
    Vaccine; 2009 Dec 10; 28(1):162-70. PubMed ID: 19799847
    [Abstract] [Full Text] [Related]

  • 7. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
    Shirai M, Arichi T, Nishioka M, Nomura T, Ikeda K, Kawanishi K, Engelhard VH, Feinstone SM, Berzofsky JA.
    J Immunol; 1995 Mar 15; 154(6):2733-42. PubMed ID: 7533182
    [Abstract] [Full Text] [Related]

  • 8. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein.
    Engelhard VH, Lacy E, Ridge JP.
    J Immunol; 1991 Feb 15; 146(4):1226-32. PubMed ID: 1704033
    [Abstract] [Full Text] [Related]

  • 9. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice.
    Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, Sette A.
    Eur J Immunol; 1996 Jan 15; 26(1):97-101. PubMed ID: 8566090
    [Abstract] [Full Text] [Related]

  • 10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 11. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
    Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY.
    J Immunol; 1998 Sep 15; 161(6):3186-94. PubMed ID: 9743387
    [Abstract] [Full Text] [Related]

  • 12. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.
    Breast Cancer Res Treat; 2004 Nov 15; 88(1):29-41. PubMed ID: 15538043
    [Abstract] [Full Text] [Related]

  • 13. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.
    Cancer Res; 1997 Oct 15; 57(20):4570-7. PubMed ID: 9377571
    [Abstract] [Full Text] [Related]

  • 14. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ, Rosenberg SA.
    Cancer Res; 1998 Nov 01; 58(21):4902-8. PubMed ID: 9809997
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.